{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T12:54:14Z","timestamp":1783601654386,"version":"3.55.0"},"reference-count":29,"publisher":"The Journal of Health Economics and Outcomes Research","issue":"3","funder":[{"DOI":"10.13039\/100014468","name":"Mallinckrodt Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014468","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JHEOR"],"abstract":"<jats:p>Objectives: This study quantified the burden of hypoxic respiratory failure (HRF)\/persistent pulmonary hypertension of newborn (PPHN) in preterm and term\/near-term infants (T\/NTs) by examining health care resource utilization (HRU) and charges in the United States.\n\nMethods: Preterms and T\/NTs (\u226434 and &gt;34 weeks of gestation, respectively) having HRF\/PPHN, with\/without meconium aspiration in inpatient setting from January 1, 2011-October 31, 2015 were identified from the Vizient database (first hospitalization=index hospitalization). Comorbidities, treatments, HRU, and charges during index hospitalization were evaluated among preterms and T\/NTs with HRF\/PPHN. Logistic regression was performed to evaluate mortality-related factors.\n\nResults: This retrospective study included 504 preterms and 414 T\/NTs with HRF\/PPHN. Preterms were more likely to have respiratory distress syndrome, neonatal jaundice, and anemia of prematurity than T\/NTs. Preterms had significantly longer inpatient stays (54.1 vs 29.0 days), time in a neonatal intensive care unit (34.1 vs 17.5 days), time on ventilation (4.7 vs 2.2 days), and higher total hospitalization charges ($613,350 vs $422,558) (all P&lt;0.001). Similar rates were observed for use of antibiotics (96.2% vs 95.4%), sildenafil (9.5% vs 8.2%), or inhaled nitric oxide (93.8% vs 94.2%). Preterms had a significantly higher likelihood of mortality than T\/NTs (odds ratio: 3.6, 95% confidence interval: 2.3-5.0).\n\nConclusions: The findings of more severe comorbidities, higher HRU, hospitalization charges, and mortality in preterms than in T\/NTs underscore the significant clinical and economic burden of HRF\/PPHN among infants. The results show significant unmet medical need; further research is warranted to determine new treatments and real-world evidence for improved patient outcomes.<\/jats:p>","DOI":"10.36469\/9682","type":"journal-article","created":{"date-parts":[[2019,9,25]],"date-time":"2019-09-25T17:37:21Z","timestamp":1569433041000},"page":"130-141","source":"Crossref","is-referenced-by-count":16,"title":["The Burden of Hypoxic Respiratory Failure in Preterm and Term\/Near-term Infants in the United States 2011-2015"],"prefix":"10.36469","volume":"6","author":[{"given":"Shivani","family":"Pandya","sequence":"first","affiliation":[{"name":"STATinMED Research"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Onur","family":"Baser","sequence":"additional","affiliation":[{"name":"University of Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George J.","family":"Wan","sequence":"additional","affiliation":[{"name":"Mallinckrodt Pharmaceuticals"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Belinda","family":"Lovelace","sequence":"additional","affiliation":[{"name":"Mallinckrodt Pharmaceuticals"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jim","family":"Potenziano","sequence":"additional","affiliation":[{"name":"Mallinckrodt Pharmaceuticals"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"An T.","family":"Pham","sequence":"additional","affiliation":[{"name":"University of California San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingyue","family":"Huang","sequence":"additional","affiliation":[{"name":"Mallinckrodt Pharmaceuticals"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Wang","sequence":"additional","affiliation":[{"name":"STATinMED Research"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"22273","published-online":{"date-parts":[[2019,6,19]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","unstructured":"Morel AA, Shreck E, Mally PV, et al. Clinical characteristics and factors associated with term and late preterm infants that do not respond to inhaled nitric oxide (iNO). J Perinatal Med. 2016;44(6):663-668.","DOI":"10.1515\/jpm-2015-0210"},{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Reuter S, Moser C, Baack M. Respiratory distress in the newborn. Pediatr Rev. 2014;35(10):417-428.","DOI":"10.1542\/pir.35-10-417"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"Konduri GG, Solimano A, Sokol GM, et al. A randomized trial of early versus standard inhaled nitric oxide therapy in term and near-term newborn infants with hypoxic respiratory failure. Pediatrics. 2004;113(3 Pt 1):559-564.","DOI":"10.1542\/peds.113.3.559"},{"key":"ref3","unstructured":"Wang YF, Liu CQ, Gao XR, et al. Effects of inhaled nitric oxide in neonatal hypoxemic respiratory failure from a multicenter controlled trial. Chin Med J (Engl. 2011;124(8):1156-1163."},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"Golombek SG, Young JN. Efficacy of inhaled nitric oxide for hypoxic respiratory failure in term and late preterm infants by baseline severity of illness: a pooled analysis of three clinical trials. Clin Ther. 2010;32(5):939-948.","DOI":"10.1016\/j.clinthera.2010.04.023"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Steinhorn RH. Neonatal pulmonary hypertension. Pediatr Crit Care Med. 2010;11(2 Suppl):S79-S84.","DOI":"10.1097\/PCC.0b013e3181c76cdc"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"Lowe CG, Trautwein JG. Inhaled nitric oxide therapy during the transport of neonates with persistent pulmonary hypertension or severe hypoxic respiratory failure. Eur J Pediatr. 2007;166(10):1025-1031.","DOI":"10.1007\/s00431-006-0374-y"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"Bendapudi P, Rao GG, Greenough A. Diagnosis and management of persistent pulmonary hypertension of the newborn. Paediatr Respir Rev. 2015;16(3):157-161.","DOI":"10.1016\/j.prrv.2015.02.001"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"Aschner JL, Gien J, Ambalavanan N, et al. Challenges, priorities and novel therapies for hypoxemic respiratory failure and pulmonary hypertension in the neonate. J Perinatol. 2016;36(Suppl 2):S32-S36.","DOI":"10.1038\/jp.2016.47"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"Lakshminrusimha S, Konduri GG, Steinhorn RH. Considerations in the management of hypoxemic respiratory failure and persistent pulmonary hypertension in term and late preterm neonates. J Perinatol. 2016;36(Suppl 2):S12-S19.","DOI":"10.1038\/jp.2016.44"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Nair J, Lakshminrusimha S. Update on PPHN: mechanisms and treatment. Semin Perinatol. 2014;38(2):78-91.","DOI":"10.1053\/j.semperi.2013.11.004"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"Belk KW, Laposata M, Craver C. A comparison of red blood cell transfusion utilization between anti- activated factor X and activated partial thromboplastin monitoring in patients receiving unfractionated heparin. J Thromb Haemost. 2016;14(11):2148-2157.","DOI":"10.1111\/jth.13476"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"Jain A, McNamara PJ. Persistent pulmonary hypertension of the newborn: advances in diagnosis and treatment. Semin Fetal Neonatal Med. 2015;20(4):262-271.","DOI":"10.1016\/j.siny.2015.03.001"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"Stephens AS, Lain SJ, Roberts CL, et al. Survival, hospitalization, and acute-care costs of very and moderate preterm infants in the first 6 years of life: a population-based study. J Pediatr. 2016;169:61-68.e3.","DOI":"10.1016\/j.jpeds.2015.10.028"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"Russell RB, Green NS, Steiner CA, et al. Cost of hospitalization for preterm and low birth weight infants in the United States. Pediatrics. 2007;120(1):e1-e9.","DOI":"10.1542\/peds.2006-2386"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"Ellsworth MA, Harris MN, Carey WA, et al. Off-label use of inhaled nitric oxide after release of NIH consensus statement. Pediatrics. 2015;135(4):643-648.","DOI":"10.1542\/peds.2014-3290"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"Razzaq A, Igbal Quddusi A, Nizami N. Risk factors and mortality among newborns with persistent pulmonary hypertension. Pak J Med Sci. 2013;29(5):1099-1104.","DOI":"10.12669\/pjms.295.3728"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"Sharma V, Berkelhamer SK, Lakshminrusimha S. Persistent pulmonary hypertension of the newborn. Matern Health Neonatol Perinatol. 2015;1(14).","DOI":"10.1186\/s40748-015-0015-4"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"Konduri GG, Kim UO. Advances in the diagnosis and management of persistent pulmonary hypertension of the newborn. Pediatr Clin North Am. 2009;56(3):579-600.","DOI":"10.1016\/j.pcl.2009.04.004"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"Steurer MA, Jelliffe-Pawlowski LL, Baer RJ, et al. Persistent pulmonary hypertension of the newborn in late preterm and term infants in California. Pediatrics. 2017;139(1).","DOI":"10.1542\/peds.2016-1165"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"Chandrasekharan P, Kozielski R, Kumar VH, et al. Early use of inhaled nitric oxide in preterm infants: is there a rationale for selective approach? Am J Perinatol. 2017;34(5):428-440.","DOI":"10.1055\/s-0036-1592346"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"Cole FS, Alleyne C, Barks JD, et al. NIH Consensus Development Conference statement: inhaled nitric- oxide therapy for premature infants. Pediatrics. 2011;127(2):363-369.","DOI":"10.1542\/peds.2010-3507"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"Kumar P. Use of inhaled nitric oxide in preterm infants. Pediatrics. 2014;133(1):164-170.","DOI":"10.1542\/peds.2013-3444"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"Suzuki S, Togari H, Potenziano JL, et al. Efficacy of inhaled nitric oxide in neonates with hypoxic respiratory failure and pulmonary hypertension: the Japanese experience. J Perinatal Med. 2018;46(6):657-663.","DOI":"10.1515\/jpm-2017-0040"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"Lai MY, Chu SM, Lakshminrusimha S, et al. Beyond the inhaled nitric oxide in persistent pulmonary hypertension of the newborn. Pediatr Neonatol. 2018;59(1):15-23.","DOI":"10.1016\/j.pedneo.2016.09.011"},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"Faraoni D, Nasr VG, DiNardo JA, et al. Hospital costs for neonates and children supported with extracorporeal membrane oxygenation. J Pediatr. 2016;169:69-75.e1.","DOI":"10.1016\/j.jpeds.2015.10.002"},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"Kelly LE, Ohlsson A, Shah PS. Sildenafil for pulmonary hypertension in neonates. Cochrane Database Syst Rev. 2017;8:CD005494.","DOI":"10.1002\/14651858.cd005494"},{"key":"ref27","doi-asserted-by":"publisher","unstructured":"Hall ES, Greenberg JM. Estimating community-level costs of preterm birth. Public Health. 2016;141:222-228.","DOI":"10.1016\/j.puhe.2016.09.033"},{"key":"ref28","doi-asserted-by":"publisher","unstructured":"Hsu BS, Meyer BD, Lakhani SA. Financial, resource utilization and mortality impacts of teaching hospital status on pediatric patients admitted for sepsis. Pediatr Infect Dis J. 2017;36(8):712-719.","DOI":"10.1097\/inf.0000000000001526"}],"container-title":["Journal of Health Economics and Outcomes Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/pmid\/32685586\/","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T14:40:31Z","timestamp":1748875231000},"score":1,"resource":{"primary":{"URL":"http:\/\/jheor.org\/article\/9682"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,19]]},"references-count":29,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2019,5,3]]}},"URL":"https:\/\/doi.org\/10.36469\/9682","archive":["Portico","Portico"],"relation":{},"ISSN":["2327-2236"],"issn-type":[{"value":"2327-2236","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,19]]},"article-number":"9682"}}